Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study

Cadario, G; Galluccio, A.; Pezza, M; Appino, A; Milani, Massimo; Pecora, S; Mastrandrea, F

doi:10.1185/030079907x226096

Cited by 59 publications

(51 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study in children did not evaluate immunologic parameters other than IgE and IgG (for which there was no difference between pre and post therapy) and primarily focused on clinical outcomes. Nevertheless, the immunologic results [31] did not show significant differences in DM-specific IgE and total DM-specific IgG or IgG4 between the active and placebo groups. On our study we did not measure IgG4, as the role of this subtype of IgG has not been well characterized in veterinary medicine or confirmed in the more recent literature.…”

Section: Discussionmentioning

confidence: 99%

“…The percentage decrease of clinical signs found in the SLIT group using our experimental model (48%) is similar to what is reported in human medicine using SLIT. A 45% decrease was described for the active group in a vehicle controlled study using patients with rhinoconjunctivitis [30] and 46% reduction of clinical scores was reported in an open non-controlled trial in patients with AD sensitive to dust mites [31] after one year of SLIT. Some of the published studies also report on the decreased need for rescue medications [32].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Immunologic Effects of Allergen-Specific Sublingual Immunotherapy in a Canine Model of Atopic Dermatitis: A Double Blind, Randomized, Controlled Study

K¹

2013

J Allergy Ther

View full text Add to dashboard Cite

Sublingual Allergen Specific Immunotherapy (SLIT) has been advocated for the treatment for allergies. Controlled studies are difficult to perform in humans due to the variety of allergies, diet, and allergenic exposure. This prospective, randomized, controlled study evaluated clinical and immunological effects of one year of SLIT using an experimental model of atopic dermatitis in dogs. Eighteen Beagles, sensitized to dust mites, timothy grass and ragweed were divided into control (n=6, vehicle) and active (n=12, 3 allergens) groups. Allergen challenge and scoring of clinical signs was done before and at the end of one year of SLIT. Blood was drawn at baseline, 4,8, and 12 months of SLIT and 2 months after stopping SLIT to measure allergen-specific IgE, IL-10, and TGF-beta.After 12 months of SLIT, ANOVA showed significant decrease of clinical scores for both groups (p<.0001) but no significant differences between groups. T tests within each group comparing pre vs. post treatment scores showed statistically significant decrease in the control (p=0.042) and in the SLIT group (p=0.00027). Effect size using Cohen's d was 1.182 for control and 2.1 for allergen group. Thus, decrease from baseline to post-treatment was nearly twice as large in the allergen as in the control group.Mixed results were found for allergen-specific IgE with significant decrease for dust mites (p=0.0242) and increase for ragweed (p=0.0074) at the end of the study. SLIT induced significant increase of TGF-beta (p=0.03) and IL-10 (p=0.0009) after ragweed stimulation compared to baseline and to the control group. TGF-beta increase abated after SLIT discontinuation results consistent with SLIT induced T regulatory response. Interestingly a significant increase for IL-10 after timothy stimulation was seen for both groups at the end of study (p<.0001).It is concluded that this experimental model is useful to investigate treatments for atopic dermatitis and their immunologic effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical and Immunologic Effects of Allergen-Specific Sublingual Immunotherapy in a Canine Model of Atopic Dermatitis: A Double Blind, Randomized, Controlled Study

K¹

2013

J Allergy Ther

View full text Add to dashboard Cite

show abstract

“…This administration frequency was based on the maintenance phase of SCIT (Olivry T et al 2015). In human study, administration frequency of the maintenance phase is once per day (Cadario G, et al 2007), but, as for our method, an effectiveness for dogs were clear.…”

Section: Discussionmentioning

confidence: 99%

“…This was a 38.3% reduction compared to baseline. The dogs were divided into 3 groups as defined by their improvement rate (Cadario et al 2007). A significant improvement defined as a CADESI-4 reduction of > 30%, was observed in 13 out of 17 dogs (76%).…”

Section: Out Of 20 Dogs 3 Dogs (No4 German Shepherdmentioning

confidence: 99%

See 1 more Smart Citation

Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study

Fujimura¹,

Ishimaru²

2016

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

Twenty dogs with canine atopic dermatitis (CAD) were treated with rush sublingual immunotherapy (SLIT), with a 48 hour build-up phase and 6 months maintenance phase (treated by antigen once every 3-4 weeks). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (baseline) and after 6 months. An open, non-controlled, non-randomized pilot trial was conducted to assess the effectiveness and safety of rush SLIT for environmental allergen extracts (Dematophagoides pteronyssinus and D.farinae mix and other). Three dogs dropped out and 17 dogs finished the trial. CADESI-4 at baseline was 60.6±27.1 (range 17-107, n=17). After 6 months of SLIT treatment, CADESI-4 was 37.4±36.0 (range 5-152, n=17) (p <0.01), which was a 38.3% reduction. A significant improvement, defined as a CADESI-4 reduction of > 30%, was observed in 13 out of 17 dogs (76%). A moderate improvement, defined as a CADESI-4 reduction of < = 30%, was observed in 2 dogs (12%). In the other 2 dogs (12%), CADESI-4 worsened or showed no change. However, no severe adverse effects were observed during the trial.Therefore, rush SLIT against environmental allergen extract for CAD showed effectiveness and safety as evidenced by the reduction of CADESI-4 after 6 months SLIT without severe adverse effects.

show abstract

Specific allergen immunotherapy for the treatment of atopic eczema

Tam

Calderón

Manikam

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Comparison 1 Immunotherapy versus control, Outcome 6 Use of other medications for eczema.. .. Analysis 2.1. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 1 Participant-or parentreported specific symptoms of eczema-SCORAD part C by route of immunotherapy.. .. .. .. .. Analysis 2.2. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 2 Participant-or parentreported specific symptoms of eczema-severity of sleep disturbance by route of immunotherapy.. .. .. Analysis 2.3. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 3 Participant-or parentreported specific symptoms of eczema-SCORAD part C by allergen type.. .. .. .. .. .. .. Analysis 2.4. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 4 Participant-or parentreported specific symptoms of eczema-severity of sleep disturbance by allergen type.. .. .. .. .. Analysis 2.5. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 5 Participant-or parentreported specific symptoms of eczema-SCORAD part C by participant age.. .. .. .. .. .. . Analysis 2.6. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 6 Participant-or parentreported specific symptoms of eczema-itch severity by participant age.. .. .. .. .. .. .. . Analysis 2.7. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 7 Participant-or parentreported specific symptoms of eczema-severity of sleep disturbance by participant age.. .. .. .. . Analysis 2.8. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 8 Participant-or parentreported specific symptoms of eczema-itch severity by severity at randomisation.. .. .. .. .. . Analysis 2.9. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 9 Participant-or parentreported specific symptoms of eczema-severity of sleep disturbance by severity at randomisation.. .. .. Analysis 2.10. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 10 Adverse events: any local reaction by route of immunotherapy.

show abstract

Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study

Cited by 59 publications

References 13 publications

Clinical and Immunologic Effects of Allergen-Specific Sublingual Immunotherapy in a Canine Model of Atopic Dermatitis: A Double Blind, Randomized, Controlled Study

Clinical and Immunologic Effects of Allergen-Specific Sublingual Immunotherapy in a Canine Model of Atopic Dermatitis: A Double Blind, Randomized, Controlled Study

Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study

Specific allergen immunotherapy for the treatment of atopic eczema

Contact Info

Product

Resources

About